HC Wainwright & Co. downgraded Akero Therapeutics Inc (AKRO) to Neutral from Buy on October 9, 2025. The stock is currently priced at $54.28.
This downgrade suggests increased caution regarding the company’s outlook, potentially reflecting concerns about competitive pressures, market conditions, or execution risks that could affect performance.
Akero Therapeutics, a clinical-stage biotechnology firm based in South San Francisco, focuses on developing treatments for serious metabolic diseases. The company’s lead product candidate, Efruxifermin (EFX), is undergoing evaluation in three ongoing Phase 3 studies targeting patients with metabolic dysfunction-associated steatotic liver disease (MASH).
As of November 20, 2025, Akero has a market capitalization of $4.5 billion and a trailing twelve-month EPS of -3.75. Upcoming earnings are scheduled for August 6, 2026, with an estimated EPS of -1.09 and expected revenue of $0.
Analyst consensus remains predominantly positive, with a total of 16 analysts covering the stock, including 2 Strong Buy, 7 Buy, and 7 Hold ratings. Recent actions from analysts indicate a trend of cautious sentiment, with multiple downgrades over the last 90 days, including from Wolfe Research and Jefferies on the same day as HC Wainwright's revision.